Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067944 | 0.86 | PTGDR2 (0.53) | BRD4EPAS1PTGDR2TRPA1 | |
| SCHEMBL15067255 | 0.86 | BRD4 (0.53) | BRD4EPAS1PTGDR2TRPA1 | |
| SCHEMBL21190911 | 0.80 | BRD4 (0.56) | BRD4EPAS1PTGDR2TRPA1MAPT | |
| SCHEMBL21190905 | 0.78 | BRD4 (0.48) | BRD4TRPA1ALDH1A1 | |
| SCHEMBL21652768 | 0.76 | EPAS1 (0.43) | BRD4EPAS1PTGDR2TRPA1 | |
| SCHEMBL15068104 | 0.76 | BRD4 (0.54) | BRD4EPAS1TRPA1 | |
| SCHEMBL16650562 | 0.75 | TRPA1 (0.49) | EPAS1TRPA1 | |
| SCHEMBL21191082 | 0.75 | BRD4 (0.55) | BRD4EPAS1TRPA1 | |
| SCHEMBL21190939 | 0.74 | BRD4 (0.46) | BRD4EPAS1TRPA1 | |
| SCHEMBL15067629 | 0.73 | PKM (0.43) | TRPA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885EPAS1 2025/4885PTGDR2 560/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885EPAS1 2025/4885PTGDR2 560/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885EPAS1 2025/4885PTGDR2 560/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885EPAS1 2025/4885PTGDR2 560/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885EPAS1 2025/4885PTGDR2 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.